| [1] |
Li M, Zhang Z, Li X, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway[J]. Nat Genet, 2014, 46(8):872-876.
|
| [2] |
Harder J, Waiz O, Otto F, et al. EGFR and HER2 expression in advanced biliary tract cancer[J]. World J Gastroenterol, 2009, 15(36):4511-4517.
|
| [3] |
Leone F, Cavalloni G, Pignochino Y, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma[J]. Clin Cancer Res, 2006, 12(6):1680-1685.
|
| [4] |
Kiguchi K, Carbajal S, Chan K, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma[J]. Cancer Res, 2001, 61(19):6971-6976.
|
| [5] |
Pignochino Y, Sarotto I, Peraldo-Neia C, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas[J]. BMC Cancer, 2010(10):631.
|
| [6] |
Hezel AF, Noel MS, Allen JN, et al. Phase Ⅱ study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer[J]. Br J Cancer, 2014, 111(3):430-436.
|
| [7] |
Czink E, Heining C, Weber TF, et al. Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer[J]. Z Gastroenterol, 2016, 54(5):426-430.
|
| [8] |
Sorscher S. Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab[J]. Cancer Manag Res, 2013(9):1-3.
|
| [9] |
Nam AR, Kim JW, Cha Y, et al. Therapeutic implication of HER2 in advanced biliary tract cancer[J]. Oncotarget, 2016, 7(36):58007-58021.
|
| [10] |
Giatromanolaki A, Sivridis E, Simopoulos C, et al. Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas[J]. J Surg Oncol, 2006, 94(3):242-247.
|
| [11] |
Letelier P, Garcia P, Leal P, et al. Immunohistochemical expression of vascular endothelial growth factor A in advanced gallbladder carcinoma[J]. Appl Immunohistochem Mol Morphol, 2014, 22(7):530-536.
|
| [12] |
Sun XN, Cao WG, Wang X, et al. Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma[J]. Tumour Biol, 2011, 32(6):1183-1190.
|
| [13] |
蒋雷，陈燕凌，余菲菲，等．胆囊癌组织中血管内皮生长因子C和D的表达及其与淋巴管和血管生成的关系[J]．中华肿瘤杂志，2010, 32(3):190-195.
|
| [14] |
Du Q, Jiang L, Wang X, et al. Tumor necrosis factor-α promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-κB-mediated upregulation of vascular endothelial growth factor-C[J]. Cancer Sci, 2014, 105(10):1261-1271.
|
| [15] |
Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study[J]. Lancet Oncol, 2010, 11(1):48-54.
|
| [16] |
Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase Ⅱ Consortium study[J]. J Clin Oncol, 2010, 28(21):3491-3497.
|
| [17] |
Lunardi A, Webster KA, Papa A, et al. Role of aberrant PI3K pathway activation in gallbladder tumorigenesis[J]. Oncotarget, 2014, 5(4):894-900.
|
| [18] |
Leal P, García P, Sandoval A, et al. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma[J]. Arch Pathol Lab Med, 2013, 137(4):552-557.
|
| [19] |
Leal P, García P, Sandoval A, et al. AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines[J]. Onco Targets Ther, 2013(6):1373-1384.
|
| [20] |
Wu Q, Kiguchi K, Kawamoto T, et al. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model[J]. Cancer Res, 2007, 67(8):3794-3800.
|
| [21] |
Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo[J]. Mol Cancer Ther, 2010, 9(7):1956-1967.
|
| [22] |
Keck S, Glencer AC, Rugo HS. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer[J]. Future Oncol, 2012, 8(11):1383-1396.
|
| [23] |
Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model[J]. Clin Cancer Res, 2007, 13(14):4261-4270.
|
| [24] |
Lee SJ, Lee J, Lee J, et al. Phase Ⅱ trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients[J]. Invest New Drugs, 2013, 31(6):1580-1586.
|
| [25] |
Onishi H, Kai M, Odate S, et al. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer[J]. Cancer Sci, 2011, 102(6):1144-1150.
|
| [26] |
Iwasaki H, Nakano K, Shinkai K, et al. Hedgehog Gli3 activator signal augments tumorigenicity of colorectal cancer via upregulation of adherence-related genes[J]. Cancer Sci, 2013, 104(3):328-336.
|
| [27] |
Yanai K, Nagai S, Wada J, et al. Hedgehog signaling pathway isa possible therapeutic target for gastric cancer[J]. J Surg Oncol, 2007, 95(1):55-62.
|
| [28] |
Kubo M, Nakamura M, Tasaki A, et al. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer[J]. Cancer Res, 2004, 64(17):6071-6074.
|
| [29] |
Li J, Wu T, Lu J, et al. Immunohistochemical evidence of the prognostic value of hedgehog pathway components in primary gallbladder carcinoma[J]. Surg Today, 2012, 42(8):770-775.
|
| [30] |
Matsushita S, Onishi H, Nakano K, et al. Hedgehog signaling pathway is a potential therapeutic target for gallbladder cancer[J]. Cancer Sci, 2014, 105(3):272-280.
|
| [31] |
Xie F, Xu X, Xu A, et al. Aberrant activation of Sonic hedgehog signaling in chronic cholecystitis and gallbladder carcinoma[J]. Hum Pathol, 2014, 45(3):513-521.
|
| [32] |
Kiesslich T, Mayr C, Wachter J, et al. Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer[J]. Mol Cell Biochem, 2014, 396(1/2):257-268.
|
| [33] |
Poggi L, Kolesar JM. Vismodegib for the treatment of basal cell skin cancer[J]. Am J Health Syst Pharm, 2013, 70(12):1033-1038.
|
| [34] |
Catenacci DV, Junttila MR, Karrison T, et al. Randomized phase Ⅰb/Ⅱ study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer[J].J Clin Oncol, 2015, 33(36):4284-4292.
|
| [35] |
Yoon HA, Noh MH, Kim BG, et al. Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. World J Gastroenterol, 2011, 17(35):4023-4030.
|
| [36] |
Zender S, Nickeleit I, Wuestefeld T, et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas[J]. Cancer Cell, 2013, 23(6):784-795.
|
| [37] |
Sahebjam S, Bedard PL, Castonguay V, et al. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503) [J]. Br J Cancer, 2013, 109(4):943-949.
|
| [38] |
Diaz-Padilla I, Hirte H, Oza AM, et al. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors[J]. Invest New Drugs, 2013, 31(5):1182-1191.
|
| [39] |
Li Q, Yang Z. Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations[J]. J Exp Clin Cancer Res, 2009(28):65.
|
| [40] |
Bekaii-Saab T, Phelps MA, Li X, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers[J].J Clin Oncol, 2011, 29(17):2357-2363.
|
| [41] |
Kornprat P, Rehak P, Rüschoff J, et al. Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. a systematic analysis including primary and corresponding metastatic tumours[J]. J Clin Pathol, 2006, 59(2):202-206.
|
| [42] |
Miyamoto S, Nakamura M, Shitara K, et al. Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers[J]. Clin Cancer Res, 2005, 11(9):3494-3502.
|
| [43] |
Browne BC, Crown J, Venkatesan N, et al. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells[J]. Ann Oncol, 2011, 22(1):68-73.
|
| [44] |
Wolf S, Lorenz J, Mössner J, et al. Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance[J]. World J Gastroenterol, 2010, 16(2):156-166.
|